Alarms have been sounded by Congressional watchdogs at the Government Accountability Office (GAO) regarding the prices paid jointly by federal and state governments for prescription drugs for low-income Americans under the Medicaidprogram.In a recent report, the GAO concluded that lax oversight by federal health officials is helping fuel the Medicaid funding crisis by allowing U.S. and state governments to pay too much for those medicines. The agency asserted that "inadequate oversight" is allowing drug manufacturers to avoid a law that requires them to provide discounts to Medicaid. The investigators fault the Centers for Medicare and Medicaid Services(CMS) for failing to monitor drug price data reported by drug makers, or ensuring that manufacturers provide adequate rebates to state Medicaid agencies, as required by law.
展开▼
